Companies: 10,795·Total market cap: $144.5T
Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd.

KNSANASDAQHealthcare● Active
$49.04
+$0.62(+1.28%)
Market Cap$3.7B
P/E Ratio—
52W High$59.87
52W Low$26.27
RevenueFinancialsEarnings

Kiniksa Pharmaceuticals, Ltd. (KNSA) Revenue

Annual & quarterly revenue history · segment & region breakdown

KNSA · revenue · updated Jun 9, 2026

Core revenue metrics

Kiniksa Pharmaceuticals, Ltd. trailing twelve-month (TTM) revenue is $0.75B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.75B
4-quarter sum · USD
YoY growth
+0.00%
vs FY —
Price / sales
4.89×
mktCap ÷ TTM rev
Revenue per day
$2M
Est. TTM ÷ 365
Revenue / employee
$2394K
315 employees
FY
—
FY
—
5Y CAGR
—
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Kiniksa Pharmaceuticals, Ltd. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

– · Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
KNSA revenue by year · KNSA revenue history · KNSA annual revenue data

Compare revenue vs peers

Biotechnology

Compare KNSA revenue against listed peers. Click any row to open that company's revenue tab.

Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc.
CDTX · $5.6B
→
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc.
APLS · $5.3B
→
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation
SRRK · $5.2B
→
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.
FOLD · $4.5B
→
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc.
CPRX · $3.8B
→
Veracyte, Inc.
Veracyte, Inc.
VCYT · $3.8B
→

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Kiniksa Pharmaceuticals, Ltd. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Kiniksa Pharmaceuticals, Ltd. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Kiniksa Pharmaceuticals, Ltd.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.
Price historyFinancial statementsForecast

Frequently asked questions

KNSA revenue · 4 questions

KNSA's trailing twelve-month (TTM) revenue is $0.75B. That is an increase of 0.00% year-over-year from — in FY.

KNSA revenueKNSA annual revenuewhat is KNSA revenueKNSA TTM revenue

▸ Source: FMP · Kiniksa Pharmaceuticals, Ltd. SEC filings · GAAP · Kiniksa Pharmaceuticals, Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026